Odylia CSO Harrison Brown, PhD spoke at the 2019 meeting of the American Society of Gene and Cell Therapy on the issues restricting the development and clinical application of gene therapies for rare genetic diseases. He discussed the specific challenges facing ultra-rare indications, especially those...

March 26, 2019 (Boston, MA) Odylia Therapeutics Chief Scientific Officer Harrison Brown led a workshop on the challenges and solutions to the development of AAV gene therapies for rare disorders. Held at the 3rd Annual Gene Therapy For Rare Disorders Conference in Boston, MA, this...

March 25, 2019 (Boston, MA) The inaugural meeting of the Odylia Gene Therapy Pre-Competitive Consortium has been held at the Massachusetts Eye and Ear campus in Boston, MA. This meeting brought together a select group of thought leaders in the gene therapy field...

Odylia CEO Scott Dorfman presented the Odylia concept to the National Institutes of Health and National Center for Advancing Translational Sciences (NCATS) at a conference on The Growing Promise of Gene Therapy Approaches. Please skip to 4:18:00 to see the Odylia talk and followup panel discussion.   Please click...

Aldevron and Odylia partner for gene therapy treatments of ultra-rare diseases. Odylia and Aldevron, a contract manufacturing organization specializing in the production of plasmid DNA and other biological agents, have entered into an agreement in which Aldevron is a member of Odylia. Under this agreement, Aldevron...

Odylia will be attending the International Symposium on Usher Syndrome July 19-21 in Mainz, Germany. CEO, Scott Dorfman, will be speaking during the scientific presentations on July 20 to present Odylia’s mission to move science to the clinic. Odylia will also present a poster at the...

Odylia will be attending the 2018 Annual Meeting of the American Society of Gene and Cell Therapy. We will be meeting with companies and individuals to discuss ways an Odylia partnership can quickly advance therapies for rare disease from the lab to the clinic. Visit Website...